{"ID": "DDI-DrugBank.d368.s10.p0", "TEXT1": "@DRUG$ reduces urinary excretion of @DRUG$ and may enhance its effect.", "LBL": "DDI-mechanism", "DRUGA": ["Acetazolamide", "drug", "0-12"], "DRUGB": ["quinidine", "drug", "43-51"]}
{"ID": "DDI-MedLine.d63.s5.p0", "TEXT1": "On the other hand, intrathecal @DRUG$ (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular @DRUG$ (40 micrograms).", "LBL": "DDI-effect", "DRUGA": ["naloxone", "drug", "31-38"], "DRUGB": ["morphine", "drug", "145-152"]}
{"ID": "DDI-DrugBank.d316.s1.p10", "TEXT1": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, @DRUG$, grapefruit juice, cimetidine) with @DRUG$ may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.", "LBL": "0", "DRUGA": ["erythromycin", "drug", "72-83"], "DRUGB": ["felodipine", "drug", "121-130"]}
{"ID": "DDI-DrugBank.d192.s0.p35", "TEXT1": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).", "LBL": "0", "DRUGA": ["antihistamines", "group", "400-413"], "DRUGB": ["antihistamines", "group", "491-504"]}
{"ID": "DDI-DrugBank.d48.s15.p55", "TEXT1": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, @DRUG$, @DRUG$, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "LBL": "0", "DRUGA": ["fentanyl", "drug", "140-147"], "DRUGB": ["pimozide", "drug", "150-157"]}
{"ID": "DDI-DrugBank.d60.s6.p4", "TEXT1": "@DRUG$ or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["Isoflurane", "drug", "0-9"], "DRUGB": ["NIMBEX", "brand", "258-263"]}
{"ID": "DDI-DrugBank.d106.s7.p1", "TEXT1": "The blood pressure effect of @DRUG$ tended to be greater in patients on atenolol than in patients on no other @DRUG$ therapy.", "LBL": "0", "DRUGA": ["SULAR", "brand", "29-33"], "DRUGB": ["antihypertensive", "group", "109-124"]}
{"ID": "DDI-DrugBank.d236.s18.p2", "TEXT1": "Haloperidol: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["Haloperidol", "drug", "13-23"], "DRUGB": ["amphetamines", "group", "119-130"]}
{"ID": "DDI-DrugBank.d410.s3.p3", "TEXT1": "@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "LBL": "0", "DRUGA": ["Beta Blockers", "group", "0-12"], "DRUGB": ["propranolol", "drug", "253-263"]}
{"ID": "DDI-DrugBank.d260.s0.p95", "TEXT1": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "LBL": "0", "DRUGA": ["bumetanide", "drug", "233-242"], "DRUGB": ["furosemide", "drug", "283-292"]}
